2491 related articles for article (PubMed ID: 28276433)
1. Renal cell carcinoma.
Hsieh JJ; Purdue MP; Signoretti S; Swanton C; Albiges L; Schmidinger M; Heng DY; Larkin J; Ficarra V
Nat Rev Dis Primers; 2017 Mar; 3():17009. PubMed ID: 28276433
[TBL] [Abstract][Full Text] [Related]
2. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy in metastatic renal cell carcinoma.
Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Vitale MG; Cartenì G
Future Oncol; 2016 Jan; 12(1):83-93. PubMed ID: 26617188
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
10. [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Ivanyi P; Grünwald V
Aktuelle Urol; 2015 Nov; 46(6):467-72. PubMed ID: 26556569
[TBL] [Abstract][Full Text] [Related]
11. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
[TBL] [Abstract][Full Text] [Related]
13. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
[TBL] [Abstract][Full Text] [Related]
17. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Linassier C; Carmier D; Combe P; D'Arcier BF; Bruyere F; Narciso B
Anticancer Res; 2012 Feb; 32(2):697-700. PubMed ID: 22287765
[TBL] [Abstract][Full Text] [Related]
19. [Systemic therapy of metastatic renal cell carcinoma].
Maute L; Bergmann L
Dtsch Med Wochenschr; 2016 Apr; 141(7):466-9. PubMed ID: 27031198
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeting therapy for renal cell carcinoma.
Eto M; Naito S
Int J Clin Oncol; 2006 Jun; 11(3):209-13. PubMed ID: 16850127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
